The Experts below are selected from a list of 19926 Experts worldwide ranked by ideXlab platform
Janelle Katsamas - One of the best experts on this subject based on the ideXlab platform.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Maurice H. T. Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic Keratosis.
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Eduardo Tschen, Dow Stough, W. Philip Werschler, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence L Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel (P = .0002 to P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
Andreas Katsambas - One of the best experts on this subject based on the ideXlab platform.
-
seborrhoeic Keratosis or occult malignant neoplasm of the skin
Journal of The European Academy of Dermatology and Venereology, 2002Co-Authors: Dimitris Rigopoulos, Eustathios Rallis, E Toumbisioannou, E Christophidou, Catherine Limas, Andreas KatsambasAbstract:Background Seborrhoeic Keratosis is generally considered to be a benign lesion of the skin. Observation We present the case of a 68-year-old male who presented with clinically typical seborrhoeic Keratosis that later histological examination showed partially covered an occult basal cell carcinoma. Objective To have an indication of what percentage of clinically apparent seborrhoeic keratoses may be associated with some form of histologically proven skin malignancy. Methods We carried out a retrospective analysis of approximately 23 000 histopathological examinations done on specimens from dermatological lesions. Results Fifty-nine (11.9%) clinically apparent seborrhoeic keratoses were later histologically diagnosed as basal cell carcinomas, 17 (3.4%) as squamous cell carcinomas, and five (1.01%) as malignant melanomas. Conclusions Although the association of seborrhoeic Keratosis and skin malignancy appears to be relatively uncommon, the possibility of such an association cannot be ruled out.
Lawrence L Anderson - One of the best experts on this subject based on the ideXlab platform.
-
ingenol mebutate gel for actinic Keratosis
The New England Journal of Medicine, 2012Co-Authors: Mark Lebwohl, Lawrence L Anderson, Neil A Swanson, Anita Melgaard, Zhenyi Xu, Brian BermanAbstract:Background Actinic Keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical and subclinical actinic keratoses. Topical field therapy currently requires weeks or months of treatment. We investigated the efficacy and safety of a new topical field therapy for actinic Keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk and extremities). Methods In four multicenter, randomized, double-blind studies, we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extremities to receive ingenol mebutate or placebo (vehicle), self-applied to a 25-cm2 contiguous field once daily for 3 consecutive days for lesions on the face or scalp or for 2 consecutive days for the trunk or extremities. Complete clearance (primary outcome) was assessed at 57 days, and local reactions were quantitatively measured. Results In a pooled analysis of the two trials...
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence L Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel (P = .0002 to P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
Eduardo Tschen - One of the best experts on this subject based on the ideXlab platform.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Maurice H. T. Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic Keratosis.
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Eduardo Tschen, Dow Stough, W. Philip Werschler, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence L Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel (P = .0002 to P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
George J Schmieder - One of the best experts on this subject based on the ideXlab platform.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Maurice H. T. Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic Keratosis.
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence Anderson, George J Schmieder, Eduardo Tschen, Dow Stough, W. Philip Werschler, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus , is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel ( P = .0002 to P P ≤ .0006) for patients in the ingenol mebutate gel treatment groups (range: 40.0% to 54.4%) compared with vehicle (11.7%), as was the baseline clearance rate (range: 42.0% to 57.9% for ingenol mebutate gel compared with 13.3% for vehicle, P P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
-
randomized double blind double dummy vehicle controlled study of ingenol mebutate gel 0 025 and 0 05 for actinic Keratosis
Journal of The American Academy of Dermatology, 2009Co-Authors: Lawrence L Anderson, George J Schmieder, Philip W Werschler, Eduardo Tschen, Dow Stough, Mark Ling, Janelle KatsamasAbstract:Background There is a need for improved medical approaches to the treatment of actinic Keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic Keratosis. Objective Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic Keratosis. Methods Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period. Results All 3 active treatments were significantly more effective than vehicle at clearing actinic Keratosis lesions, with a dose response observed. The partial clearance rate (primary efficacy end point) for patients treated with ingenol mebutate gel ranged from 56.0% to 75.4% compared with 21.7% for vehicle gel (P = .0002 to P Limitations Local skin responses may have suggested active treatment to investigators. Conclusions Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
